CEO of BioSculpture Technology Inc., Robert L. Cucin M.D. on their company’s new technology that addresses Obesity and Type 2 Diabetes.BioScultpture Technology has a game-changing technology which can do for obesity management and the treatment of Type 2 Diabetes what laser did for vision correction. The company’s earliest patent created the power system liposuction market, which grew to be half a billion dollars a year. Three things are unique about BioSculpture Technology:
- the product itself, which allows physicians to remove the deep fat inside the abdomen that causes type 2 Diabetes.
- the offering, which allows anybody to purchase the stock, not just wealthy investors and funds.
- the regulatory pathway uses the company’s device as a predicate.
Medical devices and treatmentsBioSculpture is bringing to the market two electronic devices for the bariatric treatment and one for the liposuction market:
- the revolutionary EVL® device for the bariatric and the liposuction markets;
- Airbrush Liposculptor IIE, a sleek electrical version of the pneumatic Airbrush® Liposculptor II currently selling;
- Airbrush® Liposculptor III, a next generation version of devices manufactured under licenses of their earliest tissue aspiration patent.